Thomas Widmann is a seasoned entrepreneur in the Life Science business. In 1997 he co-founded Actelion and acted as the companyâ€™s first CEO playing an instrumental role in its internationalisation, growth and subsequent raising of CHF 670 million for the IPO. Thomas joined Wellington in March 2003 as a Venture Partner and in 2006 became an Investment Partner of the Life Science team for the WP-III Life Science Fund.
Previously, Thomas also founded Hesperion, a highly successful international Contract Research. Organization (CRO), which is now part of Cerep SA Prior to this, as Vice President and Head of International Cardiovascular Clinical Research at Hoffmann-La Roche, he brought three drugs to international markets.
Thomas also spent six years at the University of California at San Diego (UCSD) as an assistant professor of cardiology. He studied medicine in Heidelberg and Paris and obtained his specialisation in cardiology in Geneva.